静脉溶栓超早期治疗急性致残性脑梗死临床观察  

Clinical Observation of Ultra-Early Treatment of Acute Disabling Cerebral Infarction with Intravenous Thrombolysis

作　　者：刘子芳 LIU Zifang(Luanzhou People's Hospital,Luanzhou,Hebei,China 063700)

机构地区：[1]河北省滦州市人民医院,河北滦州063700

出　　处：《中国药业》2022年第S01期66-67,共2页China Pharmaceuticals

摘　　要：目的探讨静脉溶栓对超早期治疗急性致残性脑梗死的临床疗效,及病发至到院治疗时间对疗效的影响。方法选取医院急诊卒中中心2021年3月至2022年5月收治的患者60例,以发病至到院治疗时间,分为研究组(发病至治疗时间<3 h)和对照组(发病至治疗时间≥3 h;<4.5 h),各30例。两组患者均予静脉溶栓(阿替普酶)治疗。结果研究组患者的总预后良好率为76.67%,显著高于对照组的50.00%;研究组患者治疗后的美国国立卫生院卒中量表评分、改良Rankin评分量表评分均显著低于对照组(P<0.05)。结论采用静脉溶栓超早期治疗急性致残性脑梗死,救治时间越早,患者的预后效果越好。Objective To investigate the clinical efficacy of ultra-early treatment of acute disabling cerebral infarction with intravenous thrombolysis and to the influence of the time from disease onset to hospital treatment on clinical efficacy.Methods A total of 60 patients treated in the Emergency Stroke Center of the hospital from March 2021 to May 2022 were selected and divided into the study group(time from disease onset to hospital treatment≥3h,<4.5 h)and the control group(time from disease onset to hospital treatment<3 h)according to the time from disease onset to hospital treatment,with 30 cases in each group.The patients in the two groups were given alteplase of intravenous thrombolysis.Results The total good prognosis rate in the study group was 76.67%,which was significantly higher than 50.00%of the control group(P<0.05).After treatment,the scores of NIH Stroke Scale(NIHSS)and Modified Rankin Scale(MRS)were significantly lower than those of the control group(P<0.05).Conclusion For patients with acute disabling cerebral infarction,the earlier ultra-early treatment of acute cerebral infarction with intravenous thrombolysis,the better the prognosis of the patients.

关 键 词：静脉溶栓 急性致残性脑梗死 救治时间 预后 

分 类 号：R969.4[医药卫生—药理学] R971[医药卫生—药学]